Coming off GLP-1s: why the weight comes back, and what actually protects you

This is the written version of How To: Transition From GLP-1 Without Gaining Weight — watch it on the channel, or read on.

You put in the months. You put in the money. You hit the number you had been chasing for years — and somewhere behind the relief there is a small, cold question sitting at the back of your head. What happens when I stop?

It is a fair question and it deserves a better answer than the internet normally gives it. On a chemical plant, when you pull a control valve out of a line, nobody stands around hoping the flow stays where it was. You know precisely what will happen, because you know what the valve was doing. GLP-1 medicines are a control valve on appetite. So let's look at the actual engineering: what the flow does when the valve comes out, why it does that, and which of the things people sell you as protection actually have evidence behind them. I walk this through on camera in the video above — this is the written version, with the trial data bolted on.

What the withdrawal trials actually show

Two big trials were built specifically to answer this, by taking the drug away on purpose and watching.

In the STEP 1 extension, adults who had lost an average of 17.3 per cent of their body weight over 68 weeks on weekly semaglutide came off the drug — and off the structured lifestyle programme at the same time. A year later they had put back 11.6 percentage points of it: roughly two-thirds of the loss, leaving them about 5.6 per cent below where they started. Blood pressure, lipids and blood-sugar markers drifted back toward baseline alongside it.

SURMOUNT-4 ran the same experiment with tirzepatide. Everyone took the drug openly for 36 weeks and lost about 20.9 per cent of their body weight. Then half were switched to placebo. Over the following year that group gained back 14.0 per cent of body weight, while the people who stayed on treatment lost a further 5.5 per cent.

Read those numbers properly, because they are the whole story in miniature. That is not a willpower failure. That is a drug wearing off. And a 2026 review of this literature is blunt about the obvious follow-up question: there are no validated tapering strategies. Nothing has been shown to stop the rebound by coming off slowly. Whether, when and how anyone steps down is a decision for them and their prescriber, and this article is not going to pretend otherwise.

The metabolism story is true. It is just not the whole story.

The usual explanation goes like this: you lost weight fast, your body panicked, it turned the burners down, and now the burners are stuck low while your appetite has come back at full blast. The technical name is adaptive thermogenesis — the fact that after weight loss you burn less energy than you would predict even after accounting for the fact that there is now less of you to run.

The effect is real and it has been measured. Six years after the Biggest Loser competition, contestants were still burning around 700 calories a day less than at baseline, with roughly 500 of that unexplained by their body composition. A startling number.

Here's the catch, and almost nobody quotes this part. In that same cohort, weight regain was not correlated with how much a person's metabolism had slowed. The correlation was essentially zero. If anything it ran the wrong way: the contestants who kept the most weight off were the ones showing the most metabolic slowing. A later reinterpretation by the same lab argued the enormous adaptation in that group was largely a response to the enormous sustained exercise loads they were carrying, which is why weight-loss studies with more normal activity levels do not measure anything like it.

So the honest version is this. The burn side does dip. But the evidence that a slowed metabolism is what drags the weight back on is weak, and the far better-evidenced driver sits on the other side of the balance: hunger and food reward signalling coming back up once the appetite valve is out. Every engineer knows the feeling — three days chasing a fault on the outlet, and the problem was on the inlet all along.

The thing that quietly walks out of the building

Here's the part that actually deserves the anxiety. A 2026 systematic review pooled 35 randomised trials of incretin-based weight loss and found that the median share of total weight lost that came from muscle-related tissue was about 28 per cent, with individual studies ranging from roughly 16 to 40 per cent. Around two-thirds of the drug interventions exceeded the benchmark researchers had set in advance for what an acceptable share would be.

Be fair about it, though: the same review found nearly half the non-drug weight-loss interventions blew past their benchmarks too. This is a rapid-weight-loss problem, not uniquely a drug problem. But muscle is the metabolically expensive tissue. Ship a meaningful fraction of it out of the building and you have permanently downrated the plant.

Which is why the boring stuff is not the boring stuff. It is the load-bearing wall. The best human evidence here is a Danish trial that took people through an eight-week low-calorie diet and then randomised them for a year to exercise alone, a GLP-1 alone, both together, or neither. The combination cut body-fat percentage by roughly twice as much as either strategy on its own, and it was the only arm that improved insulin sensitivity, long-term blood sugar and cardiorespiratory fitness. Same weight on the scale, very different body underneath it.

Resistance training plus enough protein is the single most consistently supported lever for changing what you lose rather than just how much. What it has not been shown to do — and I'm not going to inflate this — is prevent regain after stopping the drug. Nobody has run that trial. It changes composition. That is a different claim, and a smaller one.

The catch: the peptides have no data here at all

Which brings us to the mitochondrial peptides, MOTS-c and SS-31, and the reason they get pitched into this exact gap. The story is seductive: rather than suppressing appetite, they work on cellular energy efficiency, so in principle you would not have to keep starving to hold the line. MOTS-c does genuinely act on AMPK — the master switch that tells cells to burn rather than store — and SS-31 does genuinely stabilise the inner mitochondrial membrane. The mechanism is real, and elegant.

But here's the million-dollar question: has anyone actually tested this in people coming off a GLP-1? No. Not one trial. Go through the human MOTS-c literature and what you find is MOTS-c being measured — as a naturally circulating signal in exercise studies, in cancer cohorts, in heat-stress work. Studies where somebody administered MOTS-c to humans and tracked what happened to their weight simply do not exist. SS-31's only regulatory approval anywhere is a narrow accelerated approval in an ultra-rare inherited mitochondrial disease. Nothing to do with body weight.

So any cycle length you see quoted for this pairing is a research-setting convention, not a validated schedule. Treating it as a plan is treating a hypothesis as a protocol. Both compounds also sit squarely in the research-chemical gray market, which means nobody has checked what is in the vial for you. If you find yourself squinting at a certificate of analysis trying to work out whether it is genuine, congratulations — you have just been appointed quality manager of a supply chain you do not control.

The bottom line

Weight regain after stopping a GLP-1 is the expected behaviour of the system, not a personal failing, and the withdrawal trials predicted it before anyone posted about it. The mechanism is mostly appetite returning, with a smaller and more contested contribution from a slowed metabolism. The thing genuinely worth protecting is lean tissue, and the only interventions with real human evidence behind them are resistance training and adequate protein — which is exactly why nobody sells them to you very hard.

One housekeeping correction to the video: it groups retatrutide in with the approved drugs. As of late July 2026 retatrutide is still investigational, its phase 3 programme is running, and the manufacturer states plainly that it is legally available only inside its own trials. Everything on this page reflects the position as of late July 2026, and this stuff moves.

The mitochondrial peptides are an unproven optional extra bolted onto a foundation that most people have not built yet. Build the foundation. And whether, when or how you come off the medication is a conversation with the person who prescribed it — not with a video, and not with this article. Keep safe, keep skeptical.

Sources

1. Wilding et al., Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, 2022 — https://doi.org/10.1111/dom.14725
2. Aronne et al., Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4), JAMA, 2024 — https://doi.org/10.1001/jama.2023.24945
3. Shah et al., Clinical management of weight regain after discontinuation of GLP-1 receptor agonists, Diabetes Obes Metab, 2026 — https://doi.org/10.1111/dom.70713
4. Fothergill et al., Persistent metabolic adaptation 6 years after “The Biggest Loser” competition, Obesity, 2016 — https://doi.org/10.1002/oby.21538
5. Hall, Energy compensation and metabolic adaptation: “The Biggest Loser” study reinterpreted, Obesity, 2022 — https://doi.org/10.1002/oby.23308
6. Batsis et al., Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review, Ann Intern Med, 2026 — https://doi.org/10.7326/ANNALS-25-00478
7. Lundgren et al., Healthy weight loss maintenance with exercise, liraglutide, or both combined, N Engl J Med, 2021 — https://doi.org/10.1056/NEJMoa2028198
8. Eli Lilly, What to know about retatrutide (investigational status), accessed July 2026 — https://www.lilly.com/news/stories/what-to-know-about-retatrutide

Educational and research purposes only — not medical advice. Peptide Corner does not recommend any vendor, source, or dose. Keep safe, keep skeptical.